Deal with Laboratoires Th éa representing a total value of up to $280 million including clinical, regulatory and commercial ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Belite Bio shares rose after the pharmaceutical company reported positive results in a Phase 3 trial of its Tinalrebant drug for eye disease. Shares were up 11% to $152.00 after hitting a 52-week high ...
Clinical Trials Arena on MSN
Belite eyes tinlarebant approval after late-stage Stargardt success
While GlobalData analyst Sara Reci touted the DRAGON results as a “breakthrough” in STGD1, she noted that barriers to ...
The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced. This story first appeared in Healthy You - January 2025, The Gazette’s quarterly health publication.
HUC1-394 is a peptide-based eye drop for dry eyes, licensed from NOVACELL Technology. According to the company, HUC1-394 ...
“Dry eye treatment has become one of the most important steps in achieving higher-quality vision,” says Dr. Benjamin. “Tixel ...
Four years ago, Carolyn Adelsten woke up feeling like something was in her eye and it wouldn’t come out. She visited an eye specialist, got a diagnosis of mild dry eye disease and was told to use ...
The three-year initiative aims to develop two new treatments for glaucoma and myopia. Read more at straitstimes.com. Read ...
The Tear Film and Ocular Surface Society (TFOS) released the comprehensive TFOS Dry Eye Workshop II (DEWS II) guidelines in 2017, which served as a landmark update to the understanding and management ...
Deal with Laboratoires Théa representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results